GFE

What GFE does

GFE Blut GmbH (legal name: Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH) is a Frankfurt am Main–based molecular diagnostics company founded in 2005 by the German Red Cross to advance nucleic acid amplification technology (NAT) screening of donated blood. The company is wholly owned by three German Red Cross blood-service organizations — DRK Blutspendedienst West, DRK Blutspendedienst NSTOB, and the Blutspendedienst des Bayerischen Roten Kreuzes — and supplies approximately 50% of PCR blood screening tests used in Germany.

GFE's core product is the PoET System, a fully automated instrument that integrates sample pooling, nucleic acid extraction, and real-time PCR testing on a single platform, capable of processing up to 3,072 samples per day with a complete workflow time of about 3.5 hours. The PoET PCR Kit portfolio consists of CE-IVD-marked assays for qualitative detection of HCV, HBV, HIV-1/2, HAV, B19V, HEV, WNV, and CMV in human plasma, using multi-dye and target-plexing methodologies and a proprietary non-competitive internal control. Supporting products include extraction kits, prep reagents, and positive/negative controls. The June 2024 launch of PoET CMV made GFE the first vendor with a CE IVDR-certified IVD assay for CMV NAT screening in donated blood.

GFE generates revenue by selling PoET instruments, CE-IVD-marked PCR kits, and related consumables through direct sales to blood transfusion centers, blood banks, and clinical laboratories — primarily the German Red Cross affiliates and increasingly international customers via a March 2026 distribution partnership with Seegene Germany GmbH. Pricing is quote-based and not publicly disclosed. The company holds EN ISO 13485:2016 certification, an EC Certificate under IVDD, and an EU QMS Certificate under IVDR for Class D Devices. Leadership comprises CEO Dr. Petra Rehberger and CFO Susanne Suoka, with Dr. Holger Fey as Programme Director for the PoET System. Headcount is in the 11–50 range.

Name

GFE

Legal name

Gesellschaft zur Forschung, Entwicklung und Distribution von Diagnostika im Blutspendewesen mbH

Website

https://gfeblut.de

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

GFE Blut is a Frankfurt-based molecular diagnostics company, owned by three German Red Cross blood services, that develops the PoET System — fully automated NAT instruments and CE-IVD PCR kits — for blood transfusion centers screening donated blood for transfusion-transmitted viruses.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Blood Screening

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro industry

PRIMARYHLAHAAAH

Blood Bank, Transfusion Medicine & Immunohematology

Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

SECONDARYHLAGADAF

Molecular & Genetic Testing (PCR/NGS/qPCR)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Testing & Analytical Services

SECONDARYHLAAALAA

Molecular Diagnostics (PCR/qPCR, NGS-based assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAAALAL

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

Keywords

• Nucleic acid amplification testing
• Blood donor screening
• Molecular diagnostic kits
• Viral pathogen detection
• PCR test kits

Headquarters

HQ city

Frankfurt

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. PoET PCR Kits Sales: Sale of CE-IVD marked PCR kits for blood screening including HCV, HBV, HIV, HAV, B19V, HEV, WNV, and CMV detection.
2. PoET Instrument System: Sale and distribution of the fully automated PoET Instrument for NAT blood screening laboratories.
3. PoET Related Products: Sale of extraction kits, control kits, and related products optimized for use with the PoET system.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

GFE develops, manufactures, and sells the PoET System — a fully integrated nucleic acid amplification technology (NAT) platform for blood donor screening. The offering combines the PoET Instrument (a single-platform automated sample pooling, extraction, and real-time PCR device) with CE-IVD / IVDR-marked PCR kits for detecting HCV, HBV, HIV-1/2, HAV, B19V, HEV, WNV, and CMV in donated human plasma, plus supporting extraction kits and quality controls. Customers are blood transfusion centres, blood banks, and clinical laboratories.

Product overview

GFE offers the PoET System, a fully integrated platform for nucleic acid amplification technology (NAT) blood donor screening. The portfolio consists of the PoET Instrument (a fully automated instrument handling sample pooling, nucleic acid extraction, and PCR testing on a single platform) and a comprehensive suite of PoET PCR Kits for detecting HCV, HBV, HIV-1/2, HAV, B19V, HEV, WNV, and CMV. Supporting products include extraction kits, reagent kits, and various positive/negative controls. The company also distributes COVID-19 antigen rapid tests through partnerships with PCL Inc. and LVL Technologies.

Differentiator

Problem solved

Functional benefit

Brands

• PoET System: Fully integrated diagnostic system for molecular (NAT) screening of blood donations, covering entire workflow from sample pooling to sample preparation and PCR testing on a single platform.
• PoET Instrument
• PoET PCR Kits

Products and services

• PoET Instrument Fully automated instrument for NAT blood donor screening that integrates sample pooling, nucleic acid extraction, and real-time PCR testing on a single platform. Includes integrated Calliope software, dual extraction modules, PCR cyclers, and barcode tracking; processes up to 3,072 samples per day with complete workflow in 3.5 hours. Sold to blood transfusion centres, blood banks, and clinical laboratories.
• PoET PCR Kits CE-marked in vitro diagnostic real-time PCR kits for qualitative detection of viruses in human plasma samples from blood donations. Includes individual kits for HCV, HBV, HIV-1/2, HAV, B19V, HEV, WNV, and CMV, plus a multi-pathogen Multiscreen kit. Features multi-dye and target-plexing chemistry, dual-target designs, broad genotype coverage, and non-competitive internal controls. Sold to blood transfusion centres, blood banks, and clinical laboratories for use on the PoET Instrument.
• PoET CMV PCR Kit CE IVDR-certified IVD assay for nucleic acid amplification screening of donated blood for cytomegalovirus (CMV), enabling pooled-sample testing for cost-effective pathogen detection. Sold to blood donation services seeking to implement CMV NAT screening to reduce transfusion-transmitted CMV infections.
• PoET Related Products (Extraction Kit, Prep Reagent, Controls) Supporting products optimized for use with the PoET System, including the PoET Extraction Kit (viral nucleic acid isolation from plasma), PoET Prep Reagent, and PoET positive/negative/internal/master/HEV/WNV/CMV controls for quality monitoring of PCR reactions. Sold to PoET System customers in blood screening laboratories.

Quantifiable outcome

• Up to 3072 samples per day processing capacity
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Seegene Germany GmbHcoreChannel Partner/ Reseller/ Distributor · 4 March 2026Strategic collaboration under which Seegene will distribute GFE's products in selected countries. Seegene Germany leverages its global commercial network to distribute GFE's integrated PoET blood screening solution to laboratories and clinical customers worldwide. The two companies are also assessing opportunities for collaboration in the development of new products.
• LVL Technologies GmbH & Co. KGminorGTM or Marketing Partner · 12 March 2021Strengthening cooperation for sales and support of PCL's COVID-19 antigen rapid test. LVL provides international logistics and supply chain capabilities while GFE provides IVD regulatory expertise and customer support.
• PCL Inc.minorGTM or Marketing Partner · 30 November 2020Cooperation to promote PCL's CE-IVD certified COVID-19 Ag Gold Saliva rapid test in major parts of Europe. GFE leveraged its experience in viral testing and regulatory compliance for distribution support.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Grifols: Through its Procleix/Ultrio assays (originally with Novartis/Hologic), Grifols is one of the largest global suppliers of NAT blood screening reagents and instruments, serving the same transfusion medicine customers as GFE.
• Bio-Rad Laboratories: Markets the Samba II automated NAT platform and other molecular diagnostic products used for blood-borne virus screening, overlapping with GFE's PoET in clinical and blood-bank laboratories.
• Roche Diagnostics: Operates the cobas blood screening NAT platform (e.g., cobas 6800/8800) and a broad menu of CE-IVD PCR assays for HCV, HBV, HIV, HAV, B19V, HEV, WNV — directly competitive with PoET in European blood banks.
• Hologic: Manufactures the Panther system with Aptima blood screening assays for HIV, HCV, HBV; co-developed earlier Procleix products with Grifols, making it a direct peer in donor screening NAT.
• Abbott: Provides the m2000/Alinity m molecular system and CE-IVD blood screening assays for HIV, HCV, HBV; competes head-to-head with PoET in hospital and blood-bank accounts.

Others

• QIAGEN: Supplier of nucleic acid extraction kits, sample-prep technologies (e.g., QIAamp MinElute Virus Spin Kit cited on GFE's trademarks page) and molecular reagents underpinning PCR workflows; an enabling peer rather than direct blood-screening competitor.
• Cerus Corporation: Provides the INTERCEPT Blood System for pathogen reduction in platelets, plasma, and red cells; addresses the same blood-safety mission as PoET via a complementary technology that could shift screening demand.

Regional players

• BAG Healthcare: Germany-based diagnostics company focused on transfusion medicine products including blood group serology reagents; comparable customer base and regional footprint though serology rather than NAT products.

Broad incumbents

• Beckman Coulter (Danaher): Broader diagnostics incumbent offering immunoassay, hematology, and molecular workflow solutions to blood banks and transfusion laboratories; overlapping capability through its Access family and partnerships.

Emerging players

• Quotient: Developer of the MosaiQ molecular blood grouping and disease screening platform for donor centers; emerging direct competitor in the molecular blood-bank screening workflow addressed by PoET.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gfe-blut

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GFE